IR News
- 2023.12.04
- Notice of Confirmation of the Terms and Conditions of the New Share Issue (2nd Allotment) through Third-Party Allotment based on the Agreement to Set up a STraight-Equity Issue Program (“STEP”) and Revision of Funds to be Raised through the New Share Issue (2nd Allotment)
- 2023.12.04
- Notice Regarding Adjustment of Exercise Price
- 2023.11.14
- 四半期報告書-第19期第3四半期(2023/07/01-2023/09/30) (Japanese only)
- 2023.11.14
- Summary of Consolidated Financial Statements for the First Nine Months of Fiscal Year Ending December 31, 2023 [Japanese GAAP]
- 2023.11.14
- Revision to Earnings Forecast and Reversal of deferred tax assets for FY 2023
- 2023.11.06
- SymBio To Present Positive Data from Ongoing Phase 2a Study of IV Brincidofovir in Adenovirus Infection in Oral Presentation at the 65th American Society of Hematology (ASH) Annual Meeting
- 2023.10.25
- Notice of Confirmation of the Terms and Conditions of the New Share Issue (1st Allotment) through Third-Party Allotment based on the Agreement to Sept up a STraight-Equity Issue Program (“STEP”) and Revision of Funds to be Raised through the New Share Issue (1st Allotment)
- 2023.10.25
- Notice Regarding Adjustment of Exercise Price
- 2023.10.16
- Onconova Therapeutics announces Encouraging Rigosertib Data in RDEB-associated SCC Presented at EADV as Late Breaker
- 2023.10.12
- The Results of CRADA Study on Brincidofovir in Multiple Sclerosis Presented at the 9th Joint ECTRIMS-ACTRIMS Meeting
- 2023.10.06
- Notice of Agreement to Set up a STraight-Equity Issue Program (“STEP”) and Issue New Shares through Third-Party Allotment
- 2023.08.29
- Notice of Change of Global Chief Medical Officer and Appointment of Senior Vice President of SymBio Pharma USA, Inc.
- 2023.08.14
- Revision to Development Plan for IV Brincidofovir for BK virus
- 2023.08.04
- 四半期報告書-第19期第2四半期(2023/04/01-2023/06/30) (Japanese only)
- 2023.08.03
- Summary of Consolidated Financial Statements for the First Six Months of Fiscal Year Ending December 31, 2023 [Japanese GAAP]
- 2023.08.03
- Revision to Earnings Forecast for FY 2023
- 2023.07.20
- Notice of Personnel Changes at SymBio Pharma USA, Inc.
- 2023.06.12
- Presentation of the Results of Biomarker Research Predicting the Antitumor Effects of Brincidofovir at the 17th ICML
- 2023.06.07
- Onconova Therapeutics Announces Poster Presentation at the 2023 American Society of Clinical Oncology Annual Meeting
- 2023.05.29
- IV Brincidofovir in Adenovirus Infection achieved POC in Phase 2 Clinical Trial
- 2023.05.26
- 株主通信「SymBio VISION vol.23」(Japanese only)
- 2023.05.10
- Onconova Therapeutics announces presentation of an overview of its investigator-sponsored clinical program evaluating rigosertib monotherapy in RDEB-associated SCC at the ISID International Epidermolysis Bullosa Symposium in Osaka
- 2023.04.28
- 四半期報告書-第19期第1四半期(2023/01/01-2023/03/31) (Japanese only)
- 2023.04.27
- Summary of Consolidated Financial Statements for the First Three Months of Fiscal Year Ending December 31, 2023 [Japanese GAAP]
- 2023.04.24
- SymBio enters into a CRADA to Assess Efficacy of Brincidofovir for Epstein-Barr Virus Associated Lymphoproliferative Disease
- 2023.04.14
- Notice regarding the Issuance of Stock Acquisition Rights (Stock Options) to the Company’s Directors
- 2023.04.14
- Notice regarding the Issuance of Stock Acquisition Rights (Stock Options) to the Company’s Employees
- 2023.04.14
- 訂正臨時報告書 (Japanese only)
- 2023.04.03
- コーポレート・ガバナンスに関する報告書 2023/04/03 (Japanese only)
- 2023.03.31
- 事業計画及び成長可能性に関する事項 (Japanese only)
- 2023.03.24
- Notice of Shareholder Voting Results for the 18th Annual General Meeting of Shareholders
- 2023.03.24
- 臨時報告書 (Japanese only)
- 2023.03.24
- 訂正有価証券報告書-第18期(2022/01/01-2022/12/31) (Japanese only)
- 2023.03.23
- Notice of Appointments to the Board of Directors and substitute member of the Audit & Supervisory Committee, and Appointments of Corporate Officers
- 2023.03.23
- Notice Concerning the Issuance of Stock Acquisition Rights to Directors
- 2023.03.23
- Notice Concerning the Issuance of Stock Acquisition Rights to Employees
- 2023.03.23
- 臨時報告書 (Japanese only)
- 2023.03.23
- 有価証券報告書-第18期(2022/01/01-2022/12/31) (Japanese only)
- 2023.03.22
- Development of Brincidofovir for Multiple Sclerosis CRADA with the National Institute of Neurological Disorders and Stroke (NINDS)
- 2023.03.01
- Notice of Convocation of the 18th Ordinary General Meeting of Shareholders
- 2023.02.22
- Notification of Amendment to the Articles of Incorporation
- 2023.02.09
- Summary of Financial Statements for the Fiscal Year Ended December 31, 2022 [Japanese GAAP] (Consolidated)
- 2023.02.09
- Notice concerning non-operating expenses
- 2022.12.26
- SymBio files lawsuit against Pfizer Japan Inc. for infringement of TREAKISYM patents
- 2022.12.19
- SymBio enters into Sponsored Research Agreement for non-clinical study to verify the effectiveness of brincidofovir in a virus-infected brain tissue model
- 2022.12.16
- SymBio files lawsuit for infringement of TREAKISYM patents
- 2022.12.14
- SymBio Announces First Patient Dosed in Phase 2 Clinical Trial of Anti-viral Drug Brincidofovir IV in Australia
- 2022.12.13
- Presentation on the Anti-lymphoma Activity of Brincidofovir at the 64th ASH Annual Meeting
- 2022.11.24
- SymBio enters into Material Transfer Agreement with Penn State College of Medicine for a non-clinical study to evaluate the efficacy of brincidofovir in a polyomavirus model
- 2022.11.08
- Summary of Financial Statements for the First Nine Months of Fiscal Year Ending December 31, 2022 [Japanese GAAP] (Consolidated)
- 2022.11.08
- Revision to Earnings Forecast for FY 2022
- 2022.09.27
- Chimerix announces closing of brincidofovir sale to Emergent BioSolutions
- 2022.08.31
- Notice of Appointment of Corporate Officer
- 2022.08.22
- SymBio submits clinical trial notification to TGA for Phase 2 clinical trial of anti-viral drug brincidofovir IV for patients with BK virus infection after renal transplantation in Australia
- 2022.08.09
- The National Institute of Neurological Disorders and Stroke and SymBio Pharmaceuticals Limited will collaborate to evaluate the potential antiviral activity of brincidofovir (BCV) against Epstein Barr virus (EBV)
- 2022.08.04
- Summary of Financial Statements for the First Six Months of Fiscal Year Ending December 31, 2022 [Japanese GAAP] (Consolidated)
- 2022.08.04
- Revision to Earnings Forecast for FY 2022
- 2022.07.11
- SymBio announces the publication of the results of its Phase I/II clinical study of the rapid infusion (RI) administration of TREAKISYM liquid formulation
- 2022.06.16
- Notice of Resignation of Director
- 2022.06.14
- SymBio submits clinical trial notification to PMDA for Phase 2 clinical trial of anti-viral drug brincidofovir IV for patients with BK virus infection after renal transplantation
- 2022.06.13
- SymBio announces status of market adoption of the 10-minute Rapid Infusion (RI) administration of the TREAKISYM Liquid Formulation
- 2022.06.01
- Completion of Payment for the Issuance of New Shares and the 58th Stock Acquisition Rights through Third-party Allotment
- 2022.05.18
- Chimerix announces sale of brincidofovir to Emergent BioSolutions
- 2022.05.16
- Notice of the Issuance of New Shares and the 58th Stock Acquisition Rights through Third-party Allotment
- 2022.05.11
- Summary of Financial Statements for the First Three Months of Fiscal Year Ending December 31, 2022 [Japanese GAAP] (Consolidated)
- 2022.04.22
- Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company’s Directors
- 2022.04.22
- Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company’s Employees
- 2022.04.01
- Joint research agreement with the National Cancer Center on rare cancers
- 2022.03.31
- Notice of Renewal of Syndicated Loan Agreement
- 2022.03.30
- Notice of Shareholder Voting Results for the 17th Annual General Meeting of Shareholders
- 2022.03.29
- Notice of Appointments to the Board of Directors and the Audit & Supervisory Committee, and Appointments of Corporate Officers
- 2022.03.29
- Notice Concerning the Issuance of Stock Acquisition Rights to Directors
- 2022.03.29
- Notice Concerning the Issuance of Stock Acquisition Rights to Employees
- 2022.03.08
- SymBio announces publication the final results of its phase 3 clinical trial of TREAKISYM in r/r DLBCL
- 2022.03.07
- SymBio announces initiation of non-clinical study of brincidofovir IV for brain tumors in collaboration with Brown University, USA
- 2022.02.28
- SymBio receives approval of TREAKISYM Liquid Formulation Rapid Infusion (RI) administration
- 2022.02.25
- Response to marketing approvals of generic products
- 2022.02.24
- Notification of Amendments to the Articles of Incorporation
- 2022.02.24
- Notice regarding the transition to a company with an audit and supervisory committee and nomination of directors
- 2022.02.24
- SymBio announces results of a collaborative study with the National Institute of Infectious Diseases on adenoviruses and the antiviral agent brincidofovir
- 2022.02.10
- Summary of Financial Statements for the Fiscal Year Ended December 31, 2021 [Japanese GAAP] (Non-consolidated)
- 2022.02.10
- Notice concerning non-operating expenses
- 2022.02.10
- Notice regarding difference between earnings forecast and the actual results for the fiscal year ended December 31, 2021
- 2022.01.31
- Initiation of a phase 2 clinical trial of bendamustine and rituximab combination therapy followed by autologous hematopoietic stem cell transplantation in patients with relapsed or refractory diffuse large B-cell lymphoma
- 2022.01.18
- SymBio submits clinical trial application to MHRA for Phase 2 clinical trial of anti-viral drug brincidofovir IV for treatment of pediatric adenovirus infection
- 2022.01.06
- Joint research agreement to establish a Social Collaboration Course, Molecular Oncology, with the University of Tokyo
- 2021.12.24
- Notice of Appointment of Executive Vice President, Corporate Officer and COO
- 2021.12.20
- Notice of Appointment of Corporate Officer
- 2021.11.24
- SymBio receives approval of shelf-life extension forTREAKISYM ready-to-dilute (RTD) liquid formulation
- 2021.11.11
- Summary of Financial Statements for the Third Quarter of Fiscal Year Ending December 31, 2021 [Japanese GAAP] (Non-consolidated)
- 2021.11.11
- Notice Concerning Non-operating Expenses
- 2021.11.11
- SymBio Achieves Operating Profit for the Nine Months Ending December 31, 2021 Financial Overview for the Third Quarter of the Fiscal Year
- 2021.11.11
- SymBio announces selection of "Growth Market" as new market segment
- 2021.11.11
- Message from President of SymBio Pharma USA
- 2021.10.12
- SymBio announces commencement of operations of SymBio Pharma USA, Inc.
- 2021.09.29
- SymBio announces presentation of the final results of its Phase 3 Clinical Trial of TREAKISYM in r/r DLBCL at the 83rd Annual Meeting of the Japanese Society of Hematology
- 2021.09.27
- Onconova Therapeutics announces preliminary data on the Phase 1/2a Trial of Rigosertib-Nivolumab Combination in Advanced KRAS+ Non-Small Cell Lung Cancer
- 2021.09.21
- Initiation of controls on shipments of TREAKISYM lyophilized injection formulation
- 2021.09.08
- SymBio announces initiation of non-clinical study of brincidofovir IV at the Brain Tumor Center, Department of Neurological Surgery University of California, San Francisco
- 2021.09.01
- SymBio enters into a collaborative research agreement with the National Cancer Centre Singapore on Epstein-Barr virus positive lymphoma
- 2021.08.17
- SymBio Announces First Patient Dosed in Phase 2 Clinical Trial of anti-viral drug Brincidofovir IV
- 2021.08.04
- Analyst Report[Update report] (Shared Research)
- 2021.08.04
- Notice Concerning Non-operating Expenses
- 2021.08.04
- Summary of Financial Statements for the First Six Months of Fiscal Year Ending December 31, 2021 [Japanese GAAP] (Non-consolidated)
- 2021.08.02
- Collaborative research with Kyoto University on mechanism of response of bendamustine for diffuse large B-cell lymphoma
- 2021.07.15
- Notice of Appointment of Corporate Officer
- 2021.07.15
- Collaborative research with Gunma University to explore new indications for bendamustine and rigosertib
- 2021.06.29
- Onconova Therapeutics announces an update on the Phase 1/2a Trial of Rigosertib-Nivolumab Combination in KRAS+ Non-Small Cell Lung Cancer
- 2021.06.23
- Notice of Changes of Director
- 2021.06.18
- Onconova Therapeutics announces the synergistic anti-cancer activity of rigosertib combined with immune checkpoint blockade
- 2021.06.07
- Chimerix receives U.S. Food and Drug Administration approval for brincidofovir for the treatment of smallpox
- 2021.05.25
- New Patent Issued in Japan for Antiviral Agent Brincidofovir
- 2021.05.21
- Analyst Report[COMPANY RESEARCH AND ANALYSIS REPORT] (FISCO)
- 2021.05.19
- Chugai receives NHI price listing for polatuzumab vedotin for treatment of relapsed or refractory diffuse large B-cell lymphoma
- 2021.05.13
- Notice of Appointment of Corporate Officer
- 2021.05.13
- Summary of Financial Statements for the First Quarter of Fiscal Year Ending December 31, 2021 [Japanese GAAP] (Non-consolidated)
- 2021.05.10
- SymBio submits a partial change application for use of TREAKISYM Liquid Formulation for Rapid Infusion (RI) administration
- 2021.04.28
- SymBio receives approval for use of TREAKISYM Ready-To-Dilute (RTD) Formulation in combination with rituximab and polatuzumab vedotin for treatment of relapsed or refractory diffuse large B-cell lymphoma
- 2021.04.28
- SymBio receives approval for use of TREAKISYM Ready-To-Dilute (RTD) Formulation in combination with rituximab for treatment of relapsed or refractory diffuse large B-cell lymphoma
- 2021.04.26
- U.S. Food and Drug Administration granted fast track designation to antiviral agent brincidofovir IV for the treatment of adenovirus infection in pediatric patients
- 2021.04.26
- Onconova Therapeutics announces first patient dosed in an investigator-initiated Phase 2 study of rigosertib in recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma
- 2021.04.23
- Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees
- 2021.04.23
- Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors
- 2021.03.29
- SymBio submits partial change application to extend the shelf life of TREAKISYM Ready-To-Dilute (RTD) Formulation
- 2021.03.25
- Notice of Shareholder Voting Results for the16th Ordinary General Meeting of Shareholders
- 2021.03.25
- SymBio submits a partial change application for use of TREAKISYM Ready-To-Dilute (RTD) Formulation in combination with rituximab
for treatment of relapsed or refractory diffuse large B-cell lymphoma
- 2021.03.25
- SymBio submits a partial change application for use of TREAKISYM Ready-To-Dilute (RTD) Formulation in combination with rituximab and polatuzumab vedotin
for treatment of relapsed or refractory diffuse large B-cell lymphoma
- 2021.03.24
- Notice of Appointments to the Board of Directors and the Audit & Supervisory Board, and Appointments of Corporate Officers
- 2021.03.24
- Notice Concerning the Issuance of Stock Acquisition Rights to Directors
- 2021.03.24
- Notice Concerning the Issuance of Stock Acquisition Rights to Employees
- 2021.03.23
- SymBio receives approval for use of TREAKISYM in combination with rituximab and polatuzumab vedotin as treatment for relapsed or refractory diffuse large B-cell lymphoma
- 2021.03.23
- SymBio receives approval for use of TREAKISYM in combination with rituximab as treatment for relapsed or refractory diffuse large B-cell lymphoma
- 2021.03.11
- SymBio submits IND Application for Phase 2 Clinical Trial of Anti-viral Drug Brincidofovir IV for treatment of Pediatric Adenovirus Infection
- 2021.02.26
- Chimerix Announces FDA Extends PDUFA Date of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox to July 7, 2021
- 2021.02.25
- Notice concerning Nominations for the Board of Directors / the Audit & Supervisory Board / and Substitute Member for the Audit & Supervisory Board
- 2021.02.22
- Results of Phase III Trial of TREAKISYM in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- 2021.02.04
- 3 Year Mid-Range Plan: FY 2021 to FY 2023
- 2021.02.04
- Notice Concerning Non-Operating Income
- 2021.02.04
- Summary of Financial Statements for the Fiscal Year Ended December 31, 2020 [Japanese GAAP] (Non-consolidated)
- 2021.01.28
- Collaborative research with the Institute of Medical Science, the University of Tokyo, to explore new indications for bendamustine and rigosertib
- 2021.01.12
- Market Launch of TREAKISYM Ready-To-Dilute (RTD) Formulation
- 2020.12.23
- Notice of Appointment of Corporate Officer
- 2020.12.22
- Notice of Conclusion of Syndicated Loan Agreement
- 2020.12.18
- Completion, Monthly Exercise Status and Large Volume Exercise of the 51th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2020.12.10
- Commencement of in-house sales of the anti-cancer agent Treakisym
- 2020.12.08
- Chimerix Announces FDA Acceptance of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox
- 2020.12.03
- Notice of the Large Volume Exercise of the 51st Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2020.12.01
- Monthly Exercise Status of the 51st Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2020.11.26
- Notice of the Large Volume Exercise of the 51st Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2020.11.24
- National Health Insurance (NHI) Price Listing and Market Launch of TREAKISYM Ready-To-Dilute (RTD) Formulation
- 2020.11.11
- Notice of the Large Volume Exercise of the 51st Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2020.11.10
- Summary of Financial Statements for the First Nine Months of Fiscal Year Ending December 31, 2020 [Japanese GAAP] (Non-consolidated)
- 2020.11.10
- Notice Concerning Non-operating Expenses
- 2020.11.06
- Chimerix Completed Rolling Submission of New Drug Application to FDA for Brincidofovir as a Medical Countermeasure for Smallpox
- 2020.11.02
- Monthly Exercise Status of the 51st Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2020.10.13
- Exercise of the 51st Stock Acquisition Rights and Revision to the Specific Uses and Amounts of Funds Raised through the 50th and 51st Stock Acquisition Rights
- 2020.09.23
- SymBio Receives Approval of TREAKISYM Ready-To-Dilute (RTD) Formulation
- 2020.09.17
- Revision to Earnings Forecasts for FY 2020 and Mid-Range Plan (FY 2020 to FY 2022)
- 2020.09.09
- Last Patient Last Visit (“LPLV”) Achieved in Clinical Study for TREAKISYM Rapid Infusion Liquid Formulation
- 2020.09.07
- Preparation for Sales & Marketing by SymBio's Own Sales Organization
- 2020.09.01
- Final Arbitration Award in Dispute against The Medicines Company
- 2020.08.25
- Onconova Therapeutics Announces Topline Results from the Pivotal Phase 3 INSPIRE Trial for Higher-Risk Myelodysplastic Syndromes (HR-MDS)
- 2020.08.05
- Arbitration Award in Dispute against The Medicines Company
- 2020.08.05
- Summary of Financial Statements for the First Six Months of Fiscal Year Ending December 31, 2020 [Japanese GAAP] (Non-consolidated)
- 2020.08.05
- Notice Concerning Non-operating Expenses
- 2020.08.05
- SymBio Announces Global Development Plan of Anti-viral Drug Brincidofovir IV For Adenovirus Infectious DiseaseAfter Hematopoietic Stem Cell Transplantation
- 2020.07.30
- Onconova Therapeutics Announces that the Required Number of Survival Events Has Been Reached for the Pivotal Phase 3 INSPIRE Trial Data Analysis
- 2020.07.28
- Onconova Therapeutics Submits Application for Rigosertib to Participate in Federally Funded Human Studies in COVID-19 Disease
- 2020.07.13
- SymBio submits Partial Change Application for use of TREAKISYM in combination with polatuzumab vedotin and rituximab as treatment for relapsed or refractory diffuse large B-cell lymphoma
- 2020.07.09
- Onconova Therapeutics Announces Publication of Phase 1 Results in Leukemia Research Exploring Oral Rigosertib in Combination with Azacitidine in Higher-Risk MDS
- 2020.06.23
- Onconova Therapeutics Announces the Initiation of a Phase 1/2a Study of Rigosertib plus Nivolumab for the Treatment of KRAS+ Lung Adenocarcinoma
- 2020.06.01
- Completion, Monthly Exercise Status and Large Volume Exercise of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2020.06.01
- Monthly Exercise Status of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2020.05.15
- The 25th Congress of the European Hematology Association (25th EHA Annual Congress) Accepts Abstract for Phase III Clinical Trial of TREAKISYM in Relapsed or Refractory Diffuse Large B-Cell Lymphoma for Publication
- 2020.05.11
- SymBio submits Partial Change Application for use of TREAKISYM in combination with rituximab as treatment for relapsed or refractory diffuse large B-cell lymphoma
- 2020.05.11
- Notice of the Large Volume Exercise of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2020.05.08
- Notice of the Large Volume Exercise of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2020.05.07
- Notice of the Large Volume Exercise of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2020.05.01
- Monthly Exercise Status of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2020.04.30
- Chimerix Receives FDA Clearance for Rolling Submission of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox
- 2020.04.30
- Notice of the Large Volume Exercise of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2020.04.24
- Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company’s Directors
- 2020.04.24
- Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company’s Employees
- 2020.04.22
- Notice of Change (Retirement) of Director
- 2020.04.21
- Notice of the Large Volume Exercise of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2020.04.14
- Notice of the Large Volume Exercise of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2020.04.01
- Monthly Exercise Status of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2020.03.27
- Notice of Shareholder Voting Results for the 15th Ordinary General Meeting of Shareholders
- 2020.03.26
- Notice of Members of the Board of Director, Substitute Member of the Audit & Supervisory Board and Corporate Officers Appointment
- 2020.03.26
- Notice Concerning the Issuance of Stock Acquisition Rights to Directors
- 2020.03.26
- Notice Concerning the Issuance of Stock Acquisition Rights to Employees
- 2020.03.25
- Completion of Patient Enrollment in Clinical Trial for TREAKISYM Rapid Infusion Liquid Formulation
- 2020.03.25
- Onconova Announces Completion of Enrollment in Phase 3 INSPIRE Trial of IV Rigosertib
- 2020.03.16
- Completion of Payment for Subscription for the 50th and 51st Stock Acquisition Rights (with Exercise Price Revision Clauses)
- 2020.02.27
- Notice of the Issuance of the 50th and 51st Stock Acquisition Rights with Exercise Price Revision Clauses and Conclusion of Third-Party Allotment Agreement (Commit Issue Program)
- 2020.02.27
- Notice concerning Nominations for the Board of Directors / the Audit & Supervisory Board / and Substitute Member for the Audit & Supervisory Board
- 2020.02.12
- Completion, Monthly Exercise Status and Large Volume Exercise of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2020.02.06
- 3 Year Mid-Range Plan: FY 2020 to FY 2022
- 2020.02.06
- Notice Concerning Non-operating Expenses
- 2020.02.06
- Summary of Financial Statements for the Fiscal Year Ended December 31, 2019[Japanese GAAP] (Non-consolidated)
- 2020.02.03
- Monthly Exercise Status of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2020.01.15
- Notice of the Large Volume Exercise of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2020.01.06
- Monthly Exercise Status of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2019.12.19
- Notice of Appointment of Corporate Officer
- 2019.12.19
- Notice of the Large Volume Exercise of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2019.12.17
- Notice of the Large Volume Exercise of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2019.12.10
- Onconova Announces Data from the INSPIRE Trial and Updated Oral Rigosertib Data at the American Society of Hematology (ASH) 2019 Annual Meeting
- 2019.12.09
- Onconova Announces Collaboration with Inceptua for Pre-approval Access to Anti-cancer Drug Rigosertib
- 2019.12.02
- Monthly Exercise Status of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2019.11.27
- Notice of the Large Volume Exercise of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2019.11.25
- Notice of the Large Volume Exercise of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2019.11.12
- Notice of Instruction for Front-Loading Exercise of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment and Conclusion of Amendment Agreement
- 2019.11.08
- Summary of Financial Statements for the first nine months of fiscal year ending December 31, 2019 [Japanese GAAP] (Non-consolidated)
- 2019.11.08
- Notice Concerning Non-operating Expenses
- 2019.11.08
- Onconova Announces Presentation on Rigosertib in Myelodysplastic Syndromes at 2019 ASH Annual Meeting & Exposition
- 2019.11.05
- SymBio Announces Achievement of Primary Endpoint (Overall Response Rate) in Phase 3 Clinical Trial of TREAKISYM in relapsed/refractory diffuse large B-cell lymphoma
- 2019.10.25
- Onconova Provides Update on the Global Phase 3 INSPIRE Trial of Rigosertib in Myelodysplastic Syndromes and on Future Clinical Trial Plans
- 2019.10.18
- Notice Regarding Inappropriate Conduct of Clinical Trial Monitor
- 2019.10.01
- SymBio Announces Exclusive Global License Agreement with Chimerix for Antiviral Drug, Brincidofovir
- 2019.09.26
- SymBio Submits New Drug Application for TREAKISYM Ready-To-Dilute (RTD) Formulation
- 2019.09.18
- Progress (LPLV) of Phase 3 Clinical Trial of the Anti-cancer Drug TREAKISYM in relapsed/refractory diffuse large B-cell lymphoma
- 2019.08.07
- Revision to Earnings Forecasts for FY 2019 and Mid-Range Plan (FY 2019 to FY 2022)
- 2019.08.07
- Summary of Financial Results for the First Half of Fiscal Year Ending December 31, 2019 [Japanese GAAP] (Non-consolidated)
- 2019.08.07
- Notice Concerning Non-operating Expenses
- 2019.07.19
- Notice Regarding Sale of Fractional Shares Due to Reverse Stock Split
- 2019.06.17
- Completion, Monthly Exercise Status and Large Volume Exercise of the 46th Stock Acquisition Rights(with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2019.06.13
- Notice of the Large Volume Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2019.06.12
- Notice of Change (Resignation) of Representative Director and Appointment of Corporate Officer
- 2019.06.11
- Notice of the Large Volume Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2019.06.03
- Monthly Exercise Status of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2019.05.28
- Notice of the Large Volume Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2019.05.22
- Launch of "Regenerative Medicine" Products that can be used with the anti-cancer drug TREAKISYM as a pretreatment agent
- 2019.05.14
- Summary of Financial Results for the First Quarter of Fiscal Year Ending December 31, 2019 [Japanese GAAP] (Non-consolidated)
- 2019.05.14
- Notice Concerning Non-operating Expenses
- 2019.05.07
- Monthly Exercise Status of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2019.04.22
- Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors
- 2019.04.22
- Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees
- 2019.04.18
- Notice of the Large Volume Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2019.04.12
- Notice of the Large Volume Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2019.04.10
- Notice of the Large Volume Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2019.04.10
- First patient enrolled in Clinical Trial for TREAKISYM Rapid Infusion Liquid Formulation
- 2019.04.08
- Completion of Patient Enrollment in the Phase 3 Clinical Trial of the Anti-cancer Drug TREAKISYM for the Indication of relapsed/refractory diffuse large B-cell lymphoma
- 2019.04.01
- Monthly Exercise Status of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2019.04.01
- Onconova Announces Over 75 Percent of Planned Enrollment Achieved in Phase 3 INSPIRE Study of Rigosertib
- 2019.03.29
- Notice of Shareholder Voting Results for the 14th Ordinary General Meeting of Shareholders
- 2019.03.28
- Notice Regarding Reverse Stock Split and Amendment to the Articles of Incorporation
- 2019.03.28
- Notice Concerning the Issuance of Stock Acquisition Rights to Directors
- 2019.03.28
- Notice Concerning the Issuance of Stock Acquisition Rights to Employees
- 2019.03.28
- Notice of Board of Director, Audit & Supervisory Board, and Corporate Officer Appointments
- 2019.03.26
- TREAKISYM Approved for use as a Pretreatment to Adoptive T-Cell Therapy
- 2019.03.14
- Notice of Instruction for Front-Loading Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2019.03.05
- (Correction Notice of Press Release) Notice Regarding Reverse Stock Split and Amendment to the Articles of Incorporation
- 2019.02.28
- Notice Regarding Reverse Stock Split and Partial Amendment to Articles of Incorporation
- 2019.02.28
- Notice concerning Nominations for the Board of Directors / the Audit & Supervisory Board / and Substitute Member for the Audit & Supervisory Board
- 2019.02.07
- SymBio's Mid-Range Plan: FY 2019 to FY 2022 (Four Years)
- 2019.02.07
- Notice Concerning Non-operating Expenses
- 2019.02.07
- Summary of Financial Statements for the Fiscal Year Ended December 31, 2018[Japanese GAAP] (Non-consolidated)
- 2018.12.20
- Shipments of the 25mg Presentation of Anti-cancer Drug TREAKISYM Intravenous Infusion Paused and Shipment of Substitute
- 2018.12.17
- Completion of Exercise of the 39th Stock Acquisition Rights Issued by way of Third Party Allotment
- 2018.12.04
- Onconova Presents Results from Phase 2 Trial of Oral Rigosertib in Myelodysplastic Syndromes (MDS) at the ASH 2018 Meeting
- 2018.11.30
- Clinical Trial Begins for TREAKISYM Liquid Formulation(Rapid Infusion Injection Formulation)
- 2018.11.09
- Summary of Financial Results for the Third Quarter of Fiscal Year Ending December 31, 2018 [Japanese GAAP] (Non-consolidated)
- 2018.11.06
- Onconova Announces Presentation on Rigosertib in Myelodysplastic Syndromes at 2018 ASH Annual Meeting & Exposition
- 2018.10.17
- Onconova Announces Issuance of a New U.S. Patent for Rigosertib
- 2018.10.16
- SymBio Begins Preparation for Own Sales Organization for the Anti-Cancer Agent TREAKISYM
- 2018.10.01
- Completion and Monthly Exercise Status of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2018.10.01
- Monthly Exercise Status of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2018.09.27
- SymBio files Partial Change Application for use of TREAKISYM as a Pretreatment to Regenerative Medical Products
- 2018.09.25
- Notice of the Large Volume Exercise of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2018.09.05
- Notice of the Large Volume Exercise of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2018.09.03
- Monthly Exercise Status of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2018.08.29
- Launch of New Anti-CD20 Antibodies that can be used in combination with the anti-cancer agent TREAKISYM
- 2018.08.29
- Notice of the Large Volume Exercise of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2018.08.07
- Notice Concerning Non-operating Expenses
- 2018.08.07
- Summary of Financial Results for the First Half of Fiscal Year Ending December 31, 2018 [Japanese GAAP] (Non-consolidated)
- 2018.08.01
- Monthly Exercise Status of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2018.07.30
- Revised Medical Practice Guidelines 2018 for Healthcare Professionals
- 2018.07.25
- Notice of the Large Volume Exercise of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2018.07.09
- Eagle Announces New Patent Issued for Bendamustine Hydrochloride Injection in the U.S.
- 2018.07.04
- Notice of the Large Volume Exercise of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2018.07.02
- TREAKISYM Receives Approval for Combined Use with Anti-CD20 Antibodies
- 2018.07.02
- Monthly Exercise Status of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2018.06.18
- Eagle Announces U.S. Court Decision Granting Orphan Drug Exclusivity for Bendamustine Hydrochloride Injection in the U.S.
- 2018.06.06
- Notice of the Large Volume Exercise of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2018.06.01
- Monthly Exercise Status of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2018.05.28
- First Patient Enrolled in Phase 1 Clinical Trial for Oral TREAKISYM for Progressive Solid Tumors
- 2018.05.18
- TREAKISYM Sales Forecast for FY2018
- 2018.05.10
- Summary of Financial Results for the First Quarter of Fiscal Year Ending December 31, 2018 [Japanese GAAP] (Non-consolidated)
- 2018.05.10
- Notice Concerning Non-operating Expenses
- 2018.05.10
- Initiation of Collaborative Research with Keio University on TREAKISYM for Systemic Lupus Erythematosus
- 2018.05.01
- Monthly Exercise Status of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
- 2018.04.26
- (Correction Notice of Press Release) Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors
- 2018.04.26
- (Correction Notice of Press Release) Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees
- 2018.04.26
- Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors
- 2018.04.26
- Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees
- 2018.04.25
- Completion of Payment for Subscription for the 45th through 47th Stock Acquisition Rights (with Exercise Price Revision Clauses)
- 2018.04.18
- TREAKISYM Achieves 50% Market Share for 1st Line Low Grade Non-Hodgkin Lymphoma
- 2018.04.09
- Notice of the Issuance of the 45th through 47th Stock Acquisition Rights with Exercise Price Revision Clauses (Commit Issue Program) and Conclusion of an Unsecured Loan Facility Agreement
- 2018.03.30
- Notice of Shareholder Voting Results for the 13th Ordinary General Meeting of Shareholders
- 2018.03.29
- Notice Concerning the Issuance of Stock Acquisition Rights to Directors
- 2018.03.29
- Notice Concerning the Issuance of Stock Acquisition Rights to Employees
- 2018.03.29
- Notice of Board of Director, Audit & Supervisory Board, and Corporate Officer Appointments
- 2018.03.06
- Notice concerning Nominations for the Board of Directors/the Audit & Supervisory Board/and Substitute Member for the Audit & Supervisory Board
- 2018.02.19
- Analyst Report[Basic Report]: Fair Research updates the report
- 2018.02.09
- Termination of the Development of the Patient-controlled Pain Management Drug "SyB P-1501"
- 2018.02.07
- SymBio's Mid-Range Plan: FY2018 to FY2021
- 2018.02.07
- Summary of Financial Statements for the Fiscal Year Ended December 31, 2017 [Japanese GAAP] (Non-consolidated)
- 2018.02.07
- Notice Concerning Non-Operating Income
- 2018.01.22
- Initiation of Phase 1 Clinical Trial for Oral TREAKISYM in Progressive Solid Tumors
- 2018.01.18
- Onconova Announces Plans for the Global Randomized Phase 3 Trial of IV Rigosertib after Promising Interim Analysis
- 2017.11.30
- Termination of License Agreement between SymBio Pharmaceuticals Limited and The Medicines Company
- 2017.11.13
- Initiation of an Arbitration against The Medicines Company
- 2017.11.10
- Notice Concerning Non-operating Income
- 2017.11.10
- Summary of Financial Results for the Third Quarter of Fiscal Year Ending December 31, 2017 [Japanese GAAP] (Non-consolidated)
- 2017.11.02
- Onconova Announces Two Presentations on Rigosertib in Myelodysplastic Syndromes at 2017 ASH Annual Meeting
- 2017.10.10
- Initiation of Patient Enrollment in the Phase 1 Clinical Trial of Single-Agent Oral Rigosertib in Higher-Risk Myelodysplastic Syndromes
- 2017.09.21
- Notice of Revision to the Earnings Forecast for FY2017
- 2017.09.21
- Eagle Pharmaceuticals Licenses Japanese Rights for Bendamustine Hydrochloride Ready-to-dilute and Rapid Infusion Injection Products to SymBio Pharmaceuticals Limited
- 2017.08.31
- Initiation in Japan of the Phase 3 Clinical Trial of the Anti-cancer Drug TREAKISYM for the Indication of relapsed/refractory diffuse large B-cell lymphoma
- 2017.08.30
- Application for Partial Change of Marketing Approvals for the Anti-cancer Drug TREAKISYM
- 2017.08.25
- Completion of Payment for Subscription for the 42nd Stock Acquisition Rights by Third-Party Allotment
- 2017.08.09
- Notice of the Subscription for the 42nd Stock Acquisition Rights by Third-Party Allotment
- 2017.08.09
- Current Status of the Domestic Phase 3 Clinical Trial of the Patient-controlled Pain Management Drug "SyB P-1501"
- 2017.08.03
- Notice Concerning Non-operating Income
- 2017.08.03
- Summary of Financial Results for the Second Quarter of Fiscal Year Ending December 31, 2017[Japanese GAAP] (Non-consolidated)
- 2017.07.26
- Onconova Announces Establishment of Collaborative Research and Clinical Program Evaluating Rigosertib in Pediatric "RASopathies"
- 2017.06.30
- Initiation in Japan of the Phase 1 Clinical Trial of Single-Agent Oral Rigosertib in Higher-Risk Myelodysplastic Syndromes
- 2017.06.05
- SEC Filing by The Medicines Company as the Licensor of the Patient-controlled Pain Management Drug "SyB P-1501"
- 2017.05.11
- Summary of Financial Results for the First Quarter of Fiscal Year Ending December 31, 2017[Japanese GAAP] (Non-consolidated)
- 2017.05.11
- Notice Concerning Non-operating Expenses
- 2017.05.11
- Temporary Suspension of New Patient Enrollment in the Domestic Phase 3 Clinical Trial of the Patient-controlled Pain Management Drug "SyB P-1501"
- 2017.04.24
- Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors
- 2017.04.24
- Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees
- 2017.03.30
- Notice of Shareholder Voting Results for the 12th Ordinary General Meeting of Shareholders
- 2017.03.29
- Notice Concerning the Issuance of Stock Acquisition Rights (Stock Option) to Directors
- 2017.03.29
- Notice Concerning the Issuance of Stock Acquisition Rights (Stock Option) to Employees
- 2017.03.29
- Notice of Appointment of Members of the Board of Directors, Members of the Audit & Supervisory Board, and the Corporate Officers
- 2017.02.24
- Notice concerning the Appointment of the Representative Director and Nominations for the Board of Directors/ Auditor Candidates
- 2017.02.24
- Notice of Change to Use of Funds from the 3rd Unsecured Bonds with Convertible Bond Type Stock Acquisition Rights and the 39th Stock Acquisition Rights Issued by Third-Party Allotment
- 2017.02.09
- SymBio's Mid-Range Plan: FY2017 to FY2019
- 2017.02.09
- Summary of Financial Statements for the Fiscal Year Ended December 31, 2016[Japanese GAAP] (Non-consolidated)
- 2017.02.09
- Notice Concerning Non-Operating Income
- 2017.02.01
- Expiration of the Joint Research and Development Agreement for an Anti-cancer Drug using the TTR1 Nano-agonist Molecule
- 2016.12.19
- Approval in Japan of the Anti-cancer Drug TREAKISYM® for the Additional Indication of First-line Treatment of Low-grade Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
- 2016.12.06
- Onconova Presents Phase 2 Data from Oral Rigosertib and Azacitidine Combination Trial in Higher-Risk Myelodysplastic Syndromes at 2016 ASH Annual Meeting
- 2016.11.22
- Initiation of Patient Enrollment in the Phase 3 Clinical Trial on the Patient-controlled Pain Management Drug "SyB P-1501"
- 2016.11.14
- Notice of Shareholder Voting Results for the Extraordinary Shareholders' Meeting
- 2016.11.11
- Summary of Financial Results For the Third Quarter of Fiscal Year Ending December 31, 2016[Japanese GAAP](Non-consolidated)
- 2016.11.11
- Notice concerning Non-operating Expenses
- 2016.10.03
- Notice concerning the Change in Major and Largest Shareholder among the Company's Major Stockholders
- 2016.09.28
- Approval in Japan of the Anti-cancer Drug TREAKISYM® Intravenous Infusion 25 mg
- 2016.09.27
- Onconova Announces Results of End-of-Phase 2 Meeting with FDA regarding Plans for Pivotal Phase 3 Oral Rigosertib/Azacitidine Combination Trial for Higher-risk Myelodysplastic Syndromes
- 2016.09.15
- Notice of the Setting of the Record Date in respect of the Convocation of the Extraordinary Shareholders' Meeting
- 2016.09.15
- Notice concerning Partial Amendment to the Articles of Incorporation
- 2016.08.26
- Approval of the Anti-cancer Drug TREAKISYM® for the Additional Indication of Chronic Lymphocytic Leukemia
- 2016.08.04
- Summary of Financial Results For the Second Quarter of Fiscal Year Ending December 31, 2016[Japanese GAAP](Non-consolidated)
- 2016.08.04
- Notice Concerning Non-operating Expenses
- 2016.07.19
- Initiation of Patient Enrollment in Japan for the Global Randomized Phase 3 Trial of IV Rigosertib for Higher-risk Myelodysplastic Syndromes (MDS)
- 2016.06.16
- Corporate governance policies
- 2016.06.14
- Onconova Announces Presentation of Clinical Data from Oral Rigosertib/Azacitidine Combination Study in Higher-Risk Myelodysplastic Syndromes at EHA Annual Meeting
- 2016.06.13
- Initiation of Phase 3 Clinical Trial on the Patient-controlled Pain Management Drug "SyB P-1501"
- 2016.06.08
- Notice concerning the Change of Major Shareholder
- 2016.06.07
- Onconova Announces Poster Presentations for Oral Rigosertib/Azacitidine Combination and IV Rigosertib at 2016 ASCO Annual Meeting
- 2016.06.02
- Onconova Announces Upcoming Rigosertib Clinical Trial Presentations for 2016 ASCO Annual Meeting
- 2016.05.30
- Notice concerning the Change of Major Shareholder
- 2016.05.24
- Notice concerning the Change of Major Shareholder
- 2016.05.20
- Notice concerning Cancellation of the Extraordinary Shareholders' Meeting on July 15, 2016 and Cancellation of the Record Date therefor
- 2016.05.19
- Notice concerning the Change of Major and Largest Shareholder among the Company's Major Stockholders
- 2016.05.11
- SymBio Announces Incorporation of its U.S. Subsidiary
- 2016.05.10
- Notice of the Setting of the Record Date in respect of the Convocation of the Extraordinary Shareholders' Meeting
- 2016.05.10
- Summary of Financial Results For the First Quarter of Fiscal Year Ending December 31, 2016[Japanese GAAP](Non-consolidated)
- 2016.05.10
- Notice Concerning Non-operating Expenses
- 2016.04.22
- Completion of Payment for Subscription for the 3rd Unsecured Bonds with Convertible Bond Type Stock Acquisition Rights and the 39th Stock Acquisition Rights by Third-Party Allotment
- 2016.04.14
- Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors
- 2016.04.14
- Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees
- 2016.04.06
- Notice of the Issuance of and the Subscription for the 3rd Unsecured Bonds with Convertible Bond Type Stock Acquisition Rights and the 39th Stock Acquisition Rights by Third-Party Allotment
- 2016.03.31
- (Correction) Notice concerning partial correction to the "Notice of Appointment of Directors"
- 2016.03.31
- Notice of Shareholder Voting Results for the 11th Ordinary General Meeting of Shareholders
- 2016.03.30
- Notice Concerning the Issuance of Stock Acquisition Rights (Stock Option) to Directors
- 2016.03.30
- Notice Concerning the Issuance of Stock Acquisition Rights (Stock Option) to Employees
- 2016.03.30
- Notice of Appointment of Directors
- 2016.03.10
- Notice concerning Partial Amendment to the Articles of Incorporation and Nomination of Director Candidates
- 2016.03.10
- Onconova Announces Publication of Results from the ONTIME Trial for rigosertib in MDS
- 2016.02.10
- SymBio's Long Range Plan: FY2016 to FY2018
- 2016.02.10
- Summary of Financial Statements for the Fiscal Year Ended December 31, 2015[Japanese GAAP] (Non-consolidated)
- 2016.02.10
- Notice Concerning Non-operating Expenses
- 2016.02.08
- SymBio and Teikyo Heisei University enter into a Joint Research and Development Agreement for an Anti-cancer Drug using the TTR1 Nano-agonist Molecule
- 2016.02.04
- Assessment Status of Bendamustine in Europe
- 2015.12.28
- SymBio starts Global Phase 3 Trial for IV Rigosertib
- 2015.12.24
- SymBio Files Supplemental NDA for TREAKISYM® in First-Line Low-grade NHL and MCL
- 2015.12.24
- SymBio Files Supplemental NDA for TREAKISYM® in Chronic Lymphocytic Leukemia (Additional Indication)
- 2015.12.24
- SymBio Files Supplemental NDA for TREAKISYM® in a 25mg Vial (Different Strength)
- 2015.12.08
- Onconova to Present Results from Phase 2 Study of Oral Rigosertib in Combination with Azacitidine for MDS and AML Patients
- 2015.12.08
- Onconova Therapeutics Announces Enrollment of First Patient in Global Phase 3 Trial for IV Rigosertib
- 2015.12.07
- Start of Japan Phase I Combination Clinical Trial of Oral Rigosertib and Azacytidine in Higher-risk MDS
- 2015.11.24
- SymBio Partner Announces European Approval of IONSYS®
- 2015.11.06
- Summary of Financial Results For the Third Quarter of Fiscal Year Ending December 31, 2015[Japanese GAAP](Non-consolidated)
- 2015.11.06
- Notice Concerning Non-operating Expenses
- 2015.10.30
- Completion of Japan Phase 1 Clinical Trial for IV Rigosertib in MDS
- 2015.10.19
- Completion of TREAKISYM® Phase II Trial in Chronic Lymphocytic Leukemia
- 2015.10.19
- SymBio to Participate in Global Phase 3 Trial for IV Rigosertib
- 2015.10.05
- SymBio and The Medicines Company (Nasdaq: MDCO), announce the establishment of a strategic partnership for IONSYS® (fentanyl iontophoretic transdermal system) in Japan.
- 2015.08.28
- Onconova Announces Submission of European Clinical Trial Applications for IV Rigosertib Pivotal Phase 3 Trial in Higher-Risk MDS
- 2015.08.17
- Onconova to Present Results from Phase 2 Study of Oral Rigosertib in Combination with Azacitidine for MDS and AML Patients
- 2015.08.17
- Onconova Announces Submission of IND for IV Rigosertib Pivotal Phase 3 Trial in Higher-Risk MDS
- 2015.08.05
- Summary of Financial Results For the Second Quarter of Fiscal Year Ending December 31, 2015[Japanese GAAP](Non-consolidated)
- 2015.08.05
- Notice Concerning Non-operating income
- 2015.06.26
- Completion of Japan Phase I Trial for Oral Rigosertib (SyB C-1101) in MDS
- 2015.05.07
- Summary of Financial Results For the First Quarter of Fiscal Year Ending December 31, 2015[Japanese GAAP](Non-consolidated)
- 2015.05.07
- Notice Concerning Non-operating Expense
- 2015.04.10
- Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors
- 2015.04.10
- Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees
- 2015.03.27
- Notice of Shareholder Voting Results for the 10th Ordinary General Meeting of Shareholders
- 2015.03.26
- Notice Concerning the Issuance of Stock Acquisition Rights as Stock Option to Directors
- 2015.03.26
- Notice Concerning the Issuance of Stock Acquisition Rights as Stock Option to Employees
- 2015.03.26
- Notice of Director and Auditor Appointments
- 2015.03.18
- Notice Concerning Change in Status of Major shareholder
- 2015.03.05
- Notice of Nomination of Director Candidates and Auditor Candidates
- 2015.02.10
- SymBio's Long Range Plan: FY2015 to FY2017
- 2015.02.10
- Summary of Financial Statements for the Fiscal Year Ended December 31, 2014[Japanese GAAP] (Non-consolidated)
- 2015.02.10
- Notice Concerning Non-Operating Income
- 2015.02.03
- Onconova Announces its Clinical Development Plan for Rigosertib in MDS
- 2015.01.26
- Establishment of Sponsored ADR (American Depositary Receipt) Program
- 2015.01.13
- SEC filings for Establishment of Sponsored ADR (American Depositary Receipt) Program
- 2015.01.13
- Completion of Patient Enrollment of rigosertib (SyB L-1101, IV) Phase I Trial in Patient with refractory or relapsed myelodysplastic syndrome (MDS)
- 2014.12.24
- Notice of Revision of the Long Range Plan: FY2014 to FY2016
- 2014.12.24
- SymBio's Long Range Plan: FY2014 to FY2016 (Revised Version)
- 2014.12.01
- Completion of Payment for Subscription of the 2nd Unsecured Bonds with Convertible Bond Type Stock Acquisition Rights and the 34th Stock Acquisition Rights by Third-Party Allotment
- 2014.11.14
- Notice of the Subscription for the 2nd Unsecured Bonds with Convertible Bond Type Stock Acquisition Rights and the 34th Stock Acquisition Rights by Third-Party Allotment
- 2014.11.13
- Notice of Revision of the Financial Forecast for FY2014
- 2014.11.07
- Notice Concerning Non-Operation Income
- 2014.11.07
- Summary of Financial Results For the Third Quarter of Fiscal Year Ending December 31, 2014[Japanese GAAP](Non-consolidated)
- 2014.11.06
- Completion of Patient Enrollment of TREAKISYM® Phase II Trial in Patient with Chronic Lymphocytic Leukemia (CLL)
- 2014.09.19
- Notice Concerning Change in Status of Major shareholder
- 2014.09.18
- Notice Concerning Relocation of Head Office
- 2014.08.14
- Onconova's Announcement in the Development of Rigosertib for patients with MDS in Second Quarter 2014
- 2014.08.06
- Notice Concerning Non-Operation Expense
- 2014.08.06
- Summary of Financial Results For the Second Quarter of Fiscal Year Ending December 31, 2014[Japanese GAAP](Non-consolidated)
- 2014.06.18
- SymBio Announces Korea NDA Approval of Additional Indication for Bendamustine Hydrochloride (SyB L-0501)
- 2014.05.08
- Notice Concerning Non-Operation Expense
- 2014.05.08
- Summary of Financial Results For the First Quarter of Fiscal Year Ending December 31, 2014[Japanese GAAP](Non-consolidated)
- 2014.04.30
- Notice Concerning Adjustment to Exercise Price of Stock Option
- 2014.04.30
- Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees
- 2014.04.30
- Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors
- 2014.04.15
- Notice Concerning the Issuance of Stock Acquisition Rights as Stock Option to Employees
- 2014.04.15
- Notice Concerning the Issuance of Stock Acquisition Rights as Stock Option to Directors
- 2014.03.28
- Notice of Shareholder Voting Results for the 9th Ordinary General Meeting of Shareholders
- 2014.03.27
- Notice Concerning the Appointment of Directors
- 2014.03.27
- Announcement Personnel Changes
- 2014.03.06
- Notice Concerning the Partial Amendment to the Articles of Incorporation and Election of Directors
- 2014.03.06
- Notice Concerning the Issuance of Stock Acquisition Rights as Stock Option to Directors
- 2014.02.20
- Onconova Announces Results from Phase 3 ONTIME Study of Rigosertib in Higher Risk Myelodysplastic Syndromes (MDS)
- 2014.02.20
- SymBio's Long Range Plan: FY2014 to FY2016
- 2014.02.12
- Summary of Financial Statements for the Fiscal Year Ended December 31, 2013[Japanese GAAP](Non-consolidated)